



ABSTRACT

The present invention provides pyrazole derivatives represented by the general formula:




5

wherein R^1 represents H, an optionally substituted C₁₋₆ alkyl group etc.; one of Q and T represents a group represented by the general formula:



10 or a group represented by the general formula:



15 while the other represents an optionally substituted C₁₋₆ alkyl group etc.; R^2 represents H, a halogen atom, OH, an optionally substituted C₁₋₆ alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C₁₋₆ alkylene group etc.; Z represents $-R^B$, $-COR^C$ etc. in which R^B represents an optionally substituted C₁₋₆ alkyl group etc.; and R^C represents an optionally substituted C₁₋₆ alkyl group etc.

an optionally substituted C₁₋₆ alkyl group etc.,; R⁴ represents H, an optionally substituted C₁₋₆ alkyl group etc.; and R³, R⁵ and R⁶ represent H, a halogen atom etc., pharmaceutically acceptable salts thereof or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT1 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase of blood galactose level such as galactosemia, and pharmaceutical compositions comprising the same, pharmaceutical uses thereof, and intermediates for production thereof.